Addressing racial/ethnic disparities in cancer clinical trials: Everyone has a role to play

Cancer disproportionately impacts racial/ethnic minority groups, yet they remain underrepresented in cancer clinical trials. This commentary highlights strategies for consideration by the pharmaceutical industry to ensure diversity in therapeutic clinical trials that reflects known incidence and bur...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2021-09, Vol.127 (18), p.3282-3289
Main Authors: Habr, Dany, Ferdinand, Roxanne
Format: Article
Language:English
Subjects:
Cancer
Clinical trials
disparity
diversity
Ethnicity
Health Status Disparities
Healthcare Disparities
Humans
Minority & ethnic groups
Neoplasms - therapy
Oncology
Pharmaceutical industry
race
Racial Groups
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer disproportionately impacts racial/ethnic minority groups, yet they remain underrepresented in cancer clinical trials. This commentary highlights strategies for consideration by the pharmaceutical industry to ensure diversity in therapeutic clinical trials that reflects known incidence and burden of cancer and allows appropriate interpretation of risk/benefit with emerging therapies.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33600